静脉注射铁治疗心力衰竭:更新的系统审查和元分析
Witina Techasatian1, Yoshito Nishimura1, Manasawee Tanariyakul1
1Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, USA.
Angiology
|November 2, 2023
概括
对心力衰竭患者进行静脉注射 (IV) 铁疗法,显示了心力衰竭总住院病例的适度减少. 这份最新的综述表明,静脉注射铁可以在没有显著不良事件的情况下降低住院治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉注射 (IV) 铁给心力衰竭患者已经显示出对住院和症状的潜在益处.
- 最近的一项大型试验表明,在减少住院治疗方面,只有适度的好处,这促使进行了更新的系统性审查.
研究的目的:
- 在心力衰竭患者中对静脉注射铁的疗效和安全进行系统审查和元分析.
- 评估IV铁对心力衰竭住院,功能能力和感染率的影响.
主要方法:
- 从MEDLINE和EMBASE数据库中对研究进行系统审查和元分析,截至2023年1月9日.
- 包括13项与3410名参与者进行的研究,将静脉注射铁与对照组进行比较.
- 评估结果包括总心力衰竭住院,第一次心力衰竭住院,六分钟步行测试 (6MWT) 距离和感染发生率.
主要成果:
- 静脉注射铁并没有显著降低心血管死亡或第一次心力衰竭住院的几率.
- 观察到心力衰竭总住院病例的显著减少 (合并OR为0.63,95%CI为0.44-0.90).
- 心血管死亡和第一次心力衰竭住院的综合组合也显示出显著的减少 (合并OR为0.55,95%CI为0.47-0.64).
结论:
- 输液铁疗法在减少心力衰竭总体住院治疗方面表现出适度的有效性.
- 治疗似乎与心力衰竭住院减少而没有显著的不良事件有关.
- 进一步的研究可能会澄清IV铁在治疗心力衰竭患者中的作用.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
01:30Heart Failure IV: Classification and Diagnostic Evaluation
17
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
17
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:30Heart Failure VII: Nursing Interventions
85
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
85
01:27Heart Failure I: Introduction
14
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438